Bristol Myers Reaffirms Long-Term Financial Targets
January 08 2024 - 10:46AM
Dow Jones News
By Dean Seal
Bristol Myers Squibb reaffirmed long-term financial targets that
call for low-to-mid single-digit annual revenue growth through
2025.
The biopharmaceutical company said in an investor presentation
on Monday that it is standing behind its guidance for $8 billion to
$10 billion in growth from in-line brands from 2020 to 2025. Those
brands primarily include Immuno-Oncology, or IO, and the
anticoagulant Eliquis, according to the presentation.
Bristol Myers said it is targeting more than 37% operating
margin through 2025 and more than $10 billion in revenue from its
new product portfolio in 2026.
The company is also pushing for $25 billion in non-risk adjusted
sales for its new product portfolio in 2030.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 08, 2024 11:31 ET (16:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Oct 2023 to Oct 2024